MedPath

Health Impact of L.Reuteri Consumption in Crew Members of a Naval Ship at Sea

Not Applicable
Completed
Conditions
Gingivitis
Interventions
Dietary Supplement: Lactobacillus reuteri
Dietary Supplement: Placebo
Registration Number
NCT02775019
Lead Sponsor
Wuerzburg University Hospital
Brief Summary

This study is designed to evaluate the impact of the regular consumption of probiotic Lactobacillus reuteri-containing lozenges over a period of 42 days on parameters of oral and general health in crew members of a naval ship at sea.

Detailed Description

Probiotic strains of Lactobacillus reuteri have demonstrated a significant impact on the composition of the oral and intestinal microbiome as well as modulating the host response in several clinical trials and in vitro experiments.

This two-arm double blind placebo controlled clinical trial will evaluate the impact of the regular consumption of L.reuteri-containing lozenges over a period of 42 days on parameters of oral and general health in crew members of a naval ship at sea.

2 x 36 healthy study subjects will be recruited from the crew members of the ship.

At baseline and at the end of the study (day 42) the following parameters will be recorded at the Ramfjord teeth (teeth 16, 21, 24, 36, 41, 44):

Bleeding on Probing (BoP) as the primary outcome

Secondary outcomes will be Gingival Index (GI) Plaque Control Record (PCR) Pocket Probing Depth (PPD) Pooled oral and intestinal (stool) microbial samples will be taken at baseline and at the end of the study for the subsequent analysis of the

* composition of the oral microbiome

* composition of the intestinal microbiome by whole genome sequencing

Furthermore the frequency of short-term sick leave due to respiratory or intestinal diseases among the study participants during the observation period will be recorded.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
72
Inclusion Criteria

Minimum of 12 natural teeth

Exclusion Criteria

Regular intake of antiinflammatory drugs affecting periodontal health (e.g. NSAIDs) Manifestation of systemic disease affecting periodontal health (e.g. diabetes) Use of antiseptic oral mouthrinses Drug/alcohol abuse

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Lactobacillus reuteri lonzengesLactobacillus reuteri2x daily repeated intake of lozenges containing 10E9 CFU Lactobacillus reuteri each for 42 days
Placebo lozengesPlacebo2x daily repeated intake of lozenges being void of Lactobacillus reuteri for 42 days.
Primary Outcome Measures
NameTimeMethod
Bleeding on Probing42 days

Number of sites being positive for bleeding on probing on the Ramfjord teeth (teeth 16, 21, 24, 36, 41, 44) with 6 probing sites per tooth

Secondary Outcome Measures
NameTimeMethod
Composition of the oral microbiome42 days

Collection of pooled bacterial biofilm samples from the Ramfjord teeth for subsequent analysis by whole genome sequencing

Short-term sick leave42 days

Recording of the incidence of short-term sick leave due to gastrointestinal or respiratory diseases

Gingival Index (GI)42 days

Recording of the GI on the vestibular and oral aspects of the Ramfjord teeth (teeth 16, 21, 24, 36, 41, 44)

Composition of the intestinal microbiome42 days

Collection of microbial stool samples for subsequent analysis by whole genome sequencing

Plaque Control Record (PCR)42 days

Recording of the PCR on the vestibular and oral aspects of the Ramfjord teeth (teeth 16, 21, 24, 36, 41, 44)

Probing Pocket Depth (PPD)42 days

Recording of the PPD at the Ramfjord teeth (teeth 16, 21, 24, 36, 41, 44) with 6 probing sites per tooth

Trial Locations

Locations (1)

German Naval Medical Institute

🇩🇪

Kronshagen, Germany

© Copyright 2025. All Rights Reserved by MedPath